🇺🇸 NPH insulin in United States

1,875 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 1,875

Most-reported reactions

1. Blood Glucose Increased — 297 reports (15.84%)
2. Nausea — 244 reports (13.01%)
3. Hypoglycaemia — 203 reports (10.83%)
4. Dyspnoea — 186 reports (9.92%)
5. Vomiting — 166 reports (8.85%)
6. Asthenia — 164 reports (8.75%)
7. Diarrhoea — 162 reports (8.64%)
8. Pain — 157 reports (8.37%)
9. Fatigue — 148 reports (7.89%)
10. Weight Decreased — 148 reports (7.89%)

Source database →

Frequently asked questions

Is NPH insulin approved in United States?

NPH insulin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NPH insulin in United States?

Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.